Management of relapsed and refractory classical Hodgkin lymphoma in children and adolescents
- 7 December 2010
- journal article
- review article
- Published by Wiley in British Journal of Haematology
- Vol. 152 (3) , 249-260
Abstract
Summary: There are a number of options for salvage treatment in children and adolescents with relapsed and refractory classical Hodgkin Lymphoma. These include salvage with standard dose chemotherapy, high dose chemotherapy with autologous stem cell transplant, allogeneic stem cell transplant or other novel approach. Radiotherapy has an important role in the salvage of some patients as part of a combined modality approach. This review outlines these salvage approaches and discusses whether the evidence from paediatric studies justifies a risk‐adapted approach to salvage for individual patients or whether all patients should receive consolidation with high dose chemotherapy and autologous stem cell transplantation, which is often described as standard salvage management in adults. The important prognostic factors and how these may be used to allocate patients to standard versus high dose chemotherapy regimens are discussed. The role of allogeneic transplantation, novel agents and late effects will also be discussed.Keywords
This publication has 82 references indexed in Scilit:
- Outcome of hematopoietic stem cell transplant as salvage therapy for Hodgkin's lymphoma in adolescents and young adults at a single institutionLeukemia & Lymphoma, 2010
- A risk-adapted, response-based approach using ABVE-PC for children and adolescents with intermediate- and high-risk Hodgkin lymphoma: the results of P9425Blood, 2009
- Phase II Study of Weekly Gemcitabine and Vinorelbine for Children With Recurrent or Refractory Hodgkin's Disease: A Children's Oncology Group ReportJournal of Clinical Oncology, 2009
- Reduced intensity conditioning allogeneic stem cell transplantation for Hodgkin's lymphoma: identification of prognostic factors predicting outcomeHaematologica, 2008
- Long-term follow-up of people who have survived cancer during childhoodThe Lancet Oncology, 2006
- A pilot study of myeloablative (MA) autologous stem cell (autoSCT) followed by reduced intensity (RI) allogeneic transplantation (AlloSCT) in children and adolescents with relapsed hodgkin’s disease (HD) and non-hodgkin’s lymphoma (NHL)Transplantation and Cellular Therapy, 2006
- APE chemotherapy for children with relapsed Hodgkin disease: A Pediatric Oncology Group trialPediatric Blood & Cancer, 2005
- BEACOPP and COPP/ABVD as salvage treatment after primary extended field radiation therapy of early stage Hodgkins disease – Results of the German Hodgkin Study GroupLeukemia & Lymphoma, 2005
- Myelodysplastic syndrome and acute myeloid leukemia after autotransplantation for lymphoma: a multicenter case-control studyBlood, 2002
- New Prognostic Score Based on Treatment Outcome of Patients With Relapsed Hodgkin's Lymphoma Registered in the Database of the German Hodgkin's Lymphoma Study GroupJournal of Clinical Oncology, 2002